baber/WOPTO huggingface dataset:
Patent NZ-295659-A (NZ)
Title: Peptides derived from the autoantigen hc gp-39 (human cartilage glycoprotein) and their use in treating autoimmune articular cartilage destruction and diagnosing autoreactive t-cells
Inventor: BOOTS ANNA MARIA HELENA
IPC: A61K38/00
Filed: 1995-10-25
Abstract: PCT No. PCT/EP95/04201 Sec. 371 Date Mar. 25, 1996 Sec. 102(e) Date Mar. 25, 1996 PCT Filed Oct. 25, 1995 PCT Pub. No. WO96/13517 PCT Pub. Date May 9, 1996The present invention relates to novel peptides derived from the autoantigen HC gp-39, said peptides comprising at least one of the amino acid sequences FGRSFTLAS (SEQ ID No. 1), FTLASSETG (SEQ ID No. 2), YDDQESVKS (SEQ ID No. 3) and FSKIASNTQ (SEQ ID No. 4). The peptides resemble MHC Class II restricted T-cell epitopes present on the autoantigen HC gp-39 in articular cartilage. HC gp-39 and said peptides can be used in antigen-specific treatment of articular cartilage destruction in autoimmune diseases to induce tolerance of the immune system. The autoantigen HC gp-39 and said peptides are also suitable to induce arthritis in non-human animals, preferably mice. The invention furthermore relates to pharmaceutical compositions comprising said autoantigen and/or said peptides, a diagnostic method for the detection of autoreactive T cells in a test sample and test kits to be used in said method.
Patent NZ-314644-A (NZ)
Title: Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
Inventor: LYMAN STEWART DAVID
IPC: A61K38/18
Filed: 1994-05-12
Abstract: flt3-ligand or flt3-L optionally with a cytokine is used in the manufacture of a medicament to a)	increase the number of circulating progenitor cells or stem cells prior to cytoreductive therapy; b)	facilitate the engraftment of any transplanted progenitor cells or stems cells in a patient when the patient is receiving or has received cytoreductive therapy; c)	stimulating the proliferation of T cells in a mammal or cells of the eyrthroid lineage in the spleen of a mammal; d)	administer to a patient receiving cytoreductive therapy; e)	administer to a patient having the symptoms of myelodysplastic syndrome, anemia, and acquired immune deficiency syndrome.  It can also be used to expand progenitor cells or stem cells ex vivo or transforming hematopoietic cells prior to or during transfection with an exogenous gene ex vivo.  The cytokine can be CSF-1, EPO and IL-6.
Patent NZ-330139-A (NZ)
Title: Mowing machine including a crushing device and means to measure the revolutions and/or force by which the crushing means is driven
Inventor: MAARTEN KOORN
IPC: A01D34/66
Filed: 1997-07-11
Abstract: A mowing machine comprises a cutter bar (8) and a wheel (57) connected thereto. The wheel (57) is motor-driven. A mowing machine comprises a cutter bar (8), a crushing device (3) including a rotor (4) provided with crushing elements (5), and adjusting means by means of which the distance between the crushing elements (5) and the cutter bar (8) can be adjusted. The adjusting means are mechanically activated by means of a feeler which is mounted on the frame (23) and comes into contact with the flow of crop during operation. <IMAGE>
Patent NZ-332712-A (NZ)
Title: Polypeptide inhibitors of protein farnesyl transferase
Inventor: DOBRUSIN ELLEN MYRA
IPC: A61P43/00
Filed: 1997-04-29
Abstract: Inhibitors of protein farnesyl transferase enzymes of formula (I), wherein R1, R2, R4 & R21 are independently selected from hydrogen and alkyl, RQ is a 4-alkyleneimidazole group optionally substituted with an alkyl group on either nitrogen atom, A is -CORa, -CONHRa, -CSRa, -C(O)SRa, -C(S)ORa, -C(S)NHRa, -SO2Ra, -CONRa2 or -C(S)NRa2, wherein each Ra is independently selected from alkyl, cycloalkylalkyl, arylalkyl and heteroarylalkyl, R3 is selected from alkyl and optionally substituted  cycloalkylalkyl, arylalkyl and heteroarylalkyl and R5 is an optionally substituted C2-C3 alkylene (optionally containing an oxygen atom) terminated with one or two aryl or heteroaryl groups. The compounds are useful in treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.
Patent NZ-337168-A (NZ)
Title: Guiding of percutaneous instrument using light beam
Inventor: MCNEIRNEY JOHN C
IPC: A61B46/23
Filed: 1997-10-13
Abstract: A beam of energy such as light 66 is shone onto the body at a point of attack 71 and a chosen angle 72 to target the part 50 that is to be impinged by the biopsy needle 440.  When the light guiding tube 430, which is attached to and axially aligned with the needle, is aligned to receive the light beam 66 into end 451, the beam is transported by the tube to the visible light dispersing unit 425 so that the needle operator, either human or machine, receives an indication that the sharp end of the needle is progressing, from the point of attack and in the correct direction, toward the target 50.
Patent NZ-337218-A (NZ)
Title: linkage attached at respective ends to base and support components, and having reinforcing rib, running longitudinally, to restrict buckling, torsion and bending
Inventor: COTTERILL MICHAEL JOHN
IPC: A47B21/02
Filed: 1999-08-11
Abstract: Strut 13 has rib 10 pressed out to increase buckling resistance and is secured to a base component and a support component at respective opposite ends.  Typically strut 13 is located as part of a desk accessory enabling raising/lowering of a keyboard support.
Patent NZ-337676-A (NZ)
Title: Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
Inventor: REFF MITCHELL E
IPC: C12Q1/68
Filed: 1998-03-09
Abstract: Provided is a method for inserting DNA at a target site in the genome of a mammalian cell by: 1 transfecting or transforming a mammalian cell with a marker plasmid containing the following sequences: 1.1 a region of DNA that is heterologous to the mammalian cell genome which when integrated in the mammalian cell genome provides a unique site for homologous recombination, 1.2 a DNA fragment encoding a first inactive portion of a first selectable marker protein, and 1.3 at least one other selectable marker DNA that provides for selection of mammalian cells which have been successfully integrated with the marker plasmid; 2 selecting a cell which contains the marker plasmid integrated in its genome by screening for expression of the at least one other selectable marker DNA of step 1.3; 3 transfecting or transforming the selected cell with a target plasmid which contains the following sequences: 3.1 a region of DNA that is identical or is sufficiently homologous to the unique region in the marker plasmid such that this region of DNA can recombine with the DNA via homologous recombination, 3.2 a DNA fragment encoding a second inactive portion of the first selectable marker contained in the marker plasmid, wherein the active selectable marker protein encoded by the DNA is only produced if the fragment is expressed in association with the fragment of the selectable marker DNA contained in the marker plasmid; and 4 selecting cells which contain the target plasmid integrated at the target site by screening for the expression of the first selectable marker protein.
Patent NZ-337724-A (NZ)
Title: 1,5-dihydro-pyrazolo[3,4-d]-pyrimidinone derivatives in particular for the treatment of cardiovascular and cerebrovascular diseases, diseases of the peripheral vessels and diseases of the urogenital system
Inventor: HANING HELMUT
IPC: A61K31/505
Filed: 1998-02-26
Abstract: 1,5-dihydro-pyrazolo[3,4-d]-pyrimidinone derivatives (Formula I) which are produced by condensing the pyrimidone heterocycle on the appropriately substituted pyrazoles. The compounds are suitable as active substances in medicaments, especially in medicaments used to treat cardiovascular and cerebrovascular diseases, peripheral vascular diseases and diseases of the urogenital tract. Wherein; A and D together represent a radical of the Formula II, wherein R2 represents C6-10aryl which is optionally trisubstituted by identical or different substituents from the series consisting of nitro, cyano, trifluoromethyl, hydroxyl, halogen, carboxyl, or by straight-chain or branched acyl, alkoxy or alkoxycarbonyl; R1 represents straight chain or branched C1-4acyl or C1-10alkyl optionally substituted by hydroxyl, azido or Formula -NR3R4 or -OSO2R5; E represents straight or branched C1-10alkylene optionally substituted by hydroxyl or C=O group; L and V are identical or different and represent C6-10aryl or 5- to 7-membered aromatic; T represents a radical of the formula -CH2-X-Y-, where X represents a bond or an oxygen or sulphur atom or the -NH-group, Y represents a straight-chain or branched alkylene chain having up to 9 carbon atoms;
Patent NZ-501740-A (NZ)
Title: Antiperspirant compositions comprising a polymeric biguanide
Inventor: LOWRY MICHAEL RICHARD
IPC: A61K8/00
Filed: 1998-06-03
Abstract: The cosmetic composition for use in personal care applications comprises: A carrier, and A polymeric biguanide that contains more than two biguanide units of formula 1, and is in the form of its salt with an organic acid containing from 4 to 30 carbons, including mixtures thereof. Use of the polymeric biguanide as an antimicrobial agent in personal care formulations (e.g. to reduce malodour) is also described.
Patent NZ-502265-A (NZ)
Title: Hardened carbon steel screw with selectively hardened portions
Inventor: BAUER MARK D
IPC: F16B35/00
Filed: 2000-01-11
Abstract: A carbon steel screw is described.  The screw has one or more portions which have been selectively hardened by selective heat treatment and quenching. In one embodiment, an upper portion (24) of the screw head (12) is selectively hardened to prevent or reduce damage when torque is applied using a driving tool. The screw tip (16) may be selectively hardened for more effective penetration into a substrate. Preferably, the selectively heated portions are quenched to reduce or avoid distortion.
Patent NZ-506048-A (NZ)
Title: S-substituted 11-beta-benzaldozime-estra-4,9-dienecarbonic acid thioesters, process for their preparation and pharmaceutical preparations comprising these compounds
Inventor: SCHUBERT GERD
IPC: C07J43/00
Filed: 1999-02-10
Abstract: Thiol esters of S-substituted 11beta-benzaldoxime-estra-4,9-dien-carboxylic acids of the formula (I) and their pharmaceutically acceptable salts.  A method for their synthesis and pharmaceutical preparations containing these compounds are described. These compounds bind to progesterone receptors and have distinctly reduced anti-glucocorticoid action.
Patent NZ-506771-A (NZ)
Title: Modified factor viii
Inventor: LOLLAR JOHN S
IPC: C12N15/11
Filed: 1999-03-10
Abstract: A modified human factor VIII sequence is disclosed which is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes that are commonly developed in haemophiliacs, thus preventing uncontrollable internal bleeding caused by inhibition of factor VIII.
Patent NZ-511655-A (NZ)
Title: A pressure equalising device for a double container
Inventor: HOCHRAINER DIETER
IPC: B65D83/76
Filed: 1999-11-08
Abstract: For medical fluids, two-part containers are used which consist of an inner container and an outer container, which is impenetrable to diffusion. The inner container collapses when the fluid is removed.  For the purposes of pressure compensation between the gaseous space, disposed between the inner- and outer containers, and the surroundings of the two-part container, a pressure compensation device is required by means of which at the same time the loss of fluid through diffusion from the collapsible inner container is kept as little as possible. To that end, at least one channel is used which communicates the gas-filled intermediate space with the surroundings of the two-part container. The time constant for compensation of a pressure differential of a few millibars is within the region of quite a few hours. It is obtained by selecting the length of the channel and channel cross-section. The, at least one, channel can be produced individually, or a plurality of channels can be present in the form of pores in an open-pore sintered material or in a permeable membrane.  The pressure compensation device permits storage of the two-part container for many years, and use for many weeks as fluid is being removed in portion-wise manner. During these times, the quantity of fluid in the inner container, or the concentration thereof, changes substantially less than with the use of a known two-part container
Patent NZ-512037-A (NZ)
Title: Fence support with sleeve having webs to support wire or other lengths of material
Inventor: REID PAUL CLIFFORD
IPC: E04H17/10
Filed: 2000-06-20
Abstract: A  method  of  construction  of  a  fence  support  is characterised  by the step of fitting a sleeve  (1)  over  a support (4) for a fence, the sleeve (1) having at least  one web  (2)  configured to support lengths of material used  in the fence.
Patent NZ-518020-A (NZ)
Title: Novel composition and method for stabilizing the same
Inventor: UENO RYUJI
IPC: C07C69/738
Filed: 2000-10-13
Abstract: Disclosed is a composition comprising a bi-cyclic compound of formula (I), which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.
Patent NZ-523105-A (NZ)
Title: Agonist anti-trk-C monoclonal antibodies
Inventor: DEVAUX BRIGITTE
IPC: A61K48/00
Filed: 2001-06-22
Abstract: An agonist anti-trkC monoclonal antibody which: (a) shows no significant cross-reactivity with trkA or trkB; and (b) recognises an epitope in domain 5 of trkC and the use of said antibody in the preparation of a medicament for treating a neuropathy or neurodegenerative disease, or repairing a damaged nerve cell in a patient in need thereof.
Patent NZ-533468-A (NZ)
Title: Multistage fluid separation assembly and method
Inventor: BAKKER HILLEGONDA
Filed: 2002-12-31
Abstract: A multistage fluid separation assembly is disclosed, which comprises: one or more primary gas cooling devices (1) which each have liquefied and/or solidified condensables enriched fluid outlet (8); and a secondary fluid separation vessel (2) having a tubular vertical section (10), which vessel (2) is connected to the condensables enriched fluid outlet (8) of said primary gas cooling device(s)(1) via a tangential conduit (3)which injects said condensables enriched fluid tangentially into the tubular section (10) such that a tertiary stream (17) of liquified and/or solidified condensables is induced by gravity and centrifugal forces to swirl in downward direction alongside the inner surface of the tubular section (10) into a liquid collecting tank (19) at or near the bottom of the vessel (2) for collecting a tertiary mixture of liquified and/or solidified condensables, which tank (19) is provided with one or more heaters (20) for heating the tertiary mixture to reduce the amount of solidified condensables, such as wax, paraffins and hydrates, and with one or more liquid outlets (23, 26).
Patent NZ-533922-A (NZ)
Title: Fuel control system for mixture of fuels to combustion engine
Inventor: O'PRAY JIM
IPC: F02B3/06
Filed: 2002-12-04
Abstract: A fuel control system for controlling supply of a mixture to a combustion engine, the mixture comprising air and at least one other combustible material such as liquefied petroleum gas (LPG), includes a controller (8), a source (2) of combustible material, a first valve (S1) allowing egress of combustible material from the source in a liquid phase in response to a first activation signal, a metering valve (7) regulating supply of the combustible material into an air supply of the combustion engine, and a phase converter (4) located between the first valve (S1) and the metering valve (7) and which allows passage of the other combustible material and conversion of that combustible material from liquid phase to gaseous phase. The controller (8) regulates the supply of combustible material to the air supply via the metering valve in response to an engine speed signal received by the controller.
Patent NZ-534598-A (NZ)
Title: Pharmaceutical composition
Inventor: PENKLER LAWRENCE JOHN
IPC: A61K47/48
Filed: 2003-01-29
Abstract: Pharmaceutical compositions in freeze dried form comprising an inclusion complex of propofol and a water soluble cyclodextrin. Also disclosed is a method of making such pharmaceutical compositions.
Patent NZ-538215-A (NZ)
Title: Method and system for selecting provisioning information for mobile communication device from non-volatile memory
Inventor: SCOTT CLIFTON E
IPC: H04B1/38
Filed: 2003-08-26
Abstract: A wireless communication device is disclosed that obtains provisioning information from a removable user identification module (R-UIM) 12 if one is provided, and otherwise obtains provisioning information resident in a permanently installed onboard non-volatile memory 22, 24 such as a flash memory device.
Patent NZ-539516-A (NZ)
Title: Use of the distrontium salt of 2-[N,N-di(carboxymethyl)amino]-3-cyano-4-carboxymethyl-thiophene-5-carboxylic acid in obtaining medicaments intended for the treatment of gastro-duodenal pain
Inventor: TSOUDEROS YANNIS
IPC: A61P1/04
Filed: 2003-11-04
Abstract: Disclosed herein is a use of the distrontium salt of 2-[N,N-di(carboxymethyl)amino]-3-cyano-4-carboxymethyl-thiophene-5-carboxylic acid for the production of medicaments for the treatment of gastro-duodenal pain, wherein the gastro-duodenal pain may be associated with gastritis or duodenitis.
Patent NZ-541480-A (NZ)
Title: Use of Bv8 and/or EG-VEGF to promote hematopoiesis
Inventor: FERRARA NAPOLEONE
IPC: C12N5/077
Filed: 2004-03-12
Abstract: Disclosed is the use of Bv8 polypeptide, a polynucleotide encoding Bv8 polypeptide, EG-VEGF polypeptide, a polynucleotide encoding EG-VEGF polypeptide, or a combination thereof in the preparation of a medicament for treating an immunodeficiency disorder Also disclosed is a use of a Bv8 polypeptide antagonist, EG-VEGF polypeptide antagonist, or a combination thereof in the preparation of a medicament for treating an autoimmune disorder or a disorder associated with abnormal hematopoiesis. Also disclosed is an in vitro method for inducing proliferation of bone marrow cells, lymphoid lineage progenitor cells, or progeny thereof, comprising contacting the cells with a Bv8 polypeptide or a polynucleotide encoding Bv8 polypeptide.
Patent NZ-542477-A (NZ)
Title: Controlled release system comprising sucrose acetate isobutyrate (SAIB)
Inventor: FRAATZ KRISTINE
IPC: A61K31/4709
Filed: 2004-03-06
Abstract: Disclosed is a medicament comprising a) a pharmaceutically active constituent, b) sucrose acetate isobutyrate (SAID), c) glycerol formal or isopropylideneglycerol or a mixture thereof as solvent, and as cosolvent a pharmaceutically acceptable alcohol. Also disclosed is a medicament as above comprising a fluoroquinoline of the formula (I) or (II) pharmaceutically acceptable salts thereof, where A is N, CH or a substituted carbon as described, B is oxygen, optionally methyl- or phenyl-substituted, or phenyl- substituted NH or CH2, Z is CH or N, and wherein the rest of the subtituents are disclosed in the specification.
Patent NZ-545414-A (NZ)
Title: t-PA mutants F305H; F305H; A292S alone or in combination with R275E for the treatment of stroke because they show a significantly reduced neurotoxicity due to their increased fibrin specificity compared with wild type t-PA
Inventor: SOHNGEN MARIOLA
IPC: A61K38/49
Filed: 2002-10-31
Abstract: Disclosed is the use of a plasminogen activating factor for the manufacture of a medicament for the treatment of stroke in a human at least 3 hours after onset of the stroke, wherein the plasminogen activating factor does not exhibit a neurodegenerative effect of wild type t-PA, and the plasminogen activating factor is not Desmodus rotundus salivary plasminogen activator (DSPA).
Patent NZ-545418-A (NZ)
Title: Wood treating formulation based on solutions of styrene and furfuryl alcohol
Inventor: SCHNEIDER MARC H
IPC: B27K3/15
Filed: 2004-08-13
Abstract: Disclosed is a wood treating formulation, comprising a single solution, said solution being a mixture of a first solution comprising styrene and a styrene initiator, said initiator being present in amount of about 1% or greater based on styrene, mixed together with a second solution comprising furfuryl alcohol and a furfuryl alcohol initiator, said initiator being present in an amount of about 5% or greater based on furfuryl alcohol. A process for producing a wood treating formulation wherein the formulation is prepared by combining a first solution containing styrene and a second solution containing furfuryl alcohol is also provided.
Patent NZ-546208-A (NZ)
Title: Adhesive composition
Inventor: CHABUT BARBARA
IPC: C09J163/00
Filed: 2004-09-22
Abstract: Disclosed is a curable adhesive composition for anchoring materials in or to concrete or masonry comprising: a. at least one polymerizable epoxy compound; b. a reactive diluent reactive with said polymerizable epoxy compound; c. from greater than about 8 wt% to about 20 wt% of reactive multifunctional acrylate accelerator, said accelerator comprising at least one acrylate that is at least tri-functional and at least one acrylate that is at least tetra-functional; and d. curing agent wherein the composition has a torqued pull out performance at about 24 hours at about room temperature of at least about 50 KN.
Patent NZ-546747-A (NZ)
Title: Stable parasiticide composition
Inventor: LAU KAI KIN
Filed: 2006-04-26
Abstract: Disclosed are parasiticidal compositions having a pH of at least 7, the composition comprising an effective amount of at least one tetramisole, an effective amount of at least one macrocyclic lactone, at least one polyol in an amount of 400-980 g/L, at least one organic acid in an amount of 0.1 to 100 g/L, and optionally an effective amount of at least one benzimidazole, salicylanilide, pyrazino isoquinoline derivative, organophosphate or mixture thereof. The compositions are used in methods of treating parasitic infections in warm-blooded animals.
Patent NZ-549191-A (NZ)
Title: Animal lifter
Inventor: STEINFORT JOHN JAMES
IPC: A01K29/00
Filed: 2005-03-22
Abstract: An animal lifting and supporting device is disclosed. The device comprises a frame member (3) having a lifting section (5) and a rear support section (7) and a support member (9) depending from the frame member at the rear support section. The support member is constructed so as to project between the hind legs of an animal to support the underneath of the rear of the animal. Additionally the device comprises a pair of hip supports (11) arranged to depend from the frame member so as to provide support via the hip bones at the opposite sides of the animal. The hip supports are located between the lifting section and the rear support section. The arrangement of the device is such that the animal may be raised or supported in cantilever fashion by lifting or supporting the lifting section.
Patent NZ-560878-A (NZ)
Title: Substituted benzoxazoles and analogues as estrogenic agents
Inventor: MALAMAS MICHAEL SOTIRIOS
IPC: A61P5/32
Filed: 2002-12-03
Abstract: Substituted benzoxazoles of formula (II) and pharmaceutically acceptable salts thereof that are estrogen receptor modulators and which are useful as estrogenic agents for treating numerous diseases are disclosed, wherein R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification.